Compare Eos Energy Enterprises Inc (EOSE) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs Gilead Sciences, Inc. — how do they compare? Eos Energy Enterprises Inc trades at $2.78 (market cap $1.01B), while Gilead Sciences, Inc. trades at $146.25 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 180.6× Eos Energy Enterprises Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and Gilead Sciences, Inc. for 111 Days on average.
| EOSE | GILD | |
|---|---|---|
Market Cap | $1.01B | $182.40B |
Volume | 39,626,541 | 4,469,821 |
Sector | Industrials | Health |
52-Week High | $19.19 | $155.80 |
52-Week Low | $2.77 | $116.74 |
Typical Hold Time | 16 Days | 111 Days |
Enterprise Value | $1.34B | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $3.10, down 4.91% today, amid a bearish technical signal. The company is in a high-growth phase, with revenue surging from $114 million in 2025 to $214 million in 2026, but it remains deeply unprofitable, with a net income margin of -246.76% in 2026. Recent positive developments include a major partnership with Google for a $350 million West Virginia project and an $87 million Department of Energy loan advance to expand manufacturing capacity.
The outlook is a high-risk, high-reward proposition. Significant revenue growth and strategic partnerships offer substantial upside potential, with a consensus price target of $7.10. However, persistent negative cash flow from operations, high debt-to-asset ratio of 91.87%, and intense competition in the energy storage sector pose severe risks to shareholder value.
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
